DSFIR Stock Analysis: DSM-Firmenich | AS
Specialty Chemicals | AS, Netherlands | Market Cap: 22.134m EUR | 12M Return: 11.9% | CH1216478797 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 59.2M
Warnings
No concerns identified
Tailwinds
Seasonality 3.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DSM-Firmenich AG is a Swiss-headquartered company founded in 1902 and based in Kaiseraugst, providing nutrition, health, and beauty solutions across four business segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The company operates globally with a presence in eight geographic regions, including Switzerland, the Netherlands, broader Europe, the Middle East and Africa, North America, Latin America, China, and the rest of Asia.
The Perfumery & Beauty segment produces scents from natural, synthetic, and biotech-derived ingredients, while Taste, Texture & Health supplies flavors, natural extracts, sugar-reduction solutions, enzymes, hydrocolloids, cultures, colorants, and plant-based proteins to food and beverage manufacturers. Health, Nutrition & Care serves early-life nutrition, dietary supplements, pharmaceuticals, medical nutrition, and biomedical materials markets with vitamins, minerals, carotenoids, probiotics, and premix solutions. The Animal Nutrition & Health segment provides vitamins, performance solutions, and data-driven precision services to livestock and aquaculture producers.
DSM-Firmenich operates as a B2B ingredient supplier rather than a consumer-facing brand, with its products embedded in the supply chains of food, beverage, personal care, pharmaceutical, and animal feed companies. The flavors and fragrances industry in which it competes is characterized by high regulatory barriers, long-standing customer relationships, and significant investment in biotechnology and sustainable sourcing.
- Perfumery & Beauty fragrance sales rise on premium demand recovery
- Animal Nutrition margins pressured by EU vitamin pricing volatility
- Merger cost synergies accelerate post DSM-Firmenich integration completion
| Net Income: -1.08b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.68 > 1.0 |
| NWC/Revenue: 47.20% < 20% (prev 44.52%; Δ 2.68% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.39b > Net Income -1.08b |
| Net Debt (4.92b) to EBITDA (3.79b): 1.30 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (250.2m) vs 12m ago -5.05% < -2% |
| Gross Margin: 38.82% > 18% (prev 34.13%; Δ 4.69% > 0.5%) |
| Asset Turnover: 28.79% > 50% (prev 40.26%; Δ -11.47% > 0%) |
| Interest Coverage Ratio: 3.23 > 6 (EBIT TTM 542.0m / Interest Expense TTM 168.0m) |
| A: 0.14 (Total Current Assets 9.98b - Total Current Liabilities 5.71b) / Total Assets 30.4b |
| B: 0.29 (Retained Earnings 8.80b / Total Assets 30.4b) |
| C: 0.02 (EBIT TTM 542.0m / Avg Total Assets 31.4b) |
| D: 1.43 (Book Value of Equity 17.8b / Total Liabilities 12.5b) |
| Altman-Z'' = 3.48 = A |
| DSRI: 1.22 (Receivables 2.35b/2.77b, Revenue 9.03b/13.0b) |
| GMI: 0.88 (GM 34.13% / 38.82%) |
| AQI: 0.98 (AQ_t 0.53 / AQ_t-1 0.54) |
| SGI: 0.69 (Revenue 9.03b / 13.0b) |
| TATA: -0.08 (NI -1.08b - CFO 1.39b) / TA 30.4b) |
| Beneish M = -3.19 (Cap -4..+1) = AA |
As of August 23, 2026, the stock is trading at EUR 90.76 with a total of 861,318 shares traded. Over the past week, the price has changed by +1.07%, over one month by +8.07%, over three months by +27.26% and over the past year by +11.93%.
Current recommended Stop Loss: 85.00 (which is 6.3% or 2.6 ATR below the current price).
DSM-Firmenich has no consensus analysts rating.
P/E Trailing = 64.1429
P/E Forward = 28.9017
P/S = 2.4444
P/B = 1.3057
P/EG = 0.8963
Revenue TTM = 9.03b EUR
EBIT TTM = 542.0m EUR
EBITDA TTM = 3.79b EUR
Long Term Debt = 5.11b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.65b EUR (from shortTermDebt, last quarter)
Debt = 7.23b EUR (from shortLongTermDebtTotal, last quarter) + Leases 463.0m
Net Debt = 4.92b EUR (calculated: Debt 7.23b - CCE 2.31b)
Enterprise Value = 27.1b EUR (22.1b + Debt 7.23b - CCE 2.31b)
Interest Coverage Ratio = 3.23 (Ebit TTM 542.0m / Interest Expense TTM 168.0m)
EV/FCF = 43.36x (Enterprise Value 27.1b / FCF TTM 624.0m)
FCF Yield = 2.31% (FCF TTM 624.0m / Enterprise Value 27.1b)
FCF Margin = 6.91% (FCF TTM 624.0m / Revenue TTM 9.03b)
Net Margin = -11.97% (Net Income TTM -1.08b / Revenue TTM 9.03b)
Gross Margin = 38.82% ((Revenue TTM 9.03b - Cost of Revenue TTM 5.53b) / Revenue TTM)
Gross Margin QoQ = 40.95% (prev 40.01%)
Tobins Q-Ratio = 0.89 (Enterprise Value 27.1b / Total Assets 30.4b)
Interest Expense / Debt = 2.32% (Interest Expense 168.0m / Debt 7.23b)
Taxrate = 21.88% (63.0m / 288.0m)
NOPAT = 423.4m (EBIT 542.0m * (1 - 21.88%))
Current Ratio = 1.75 (Total Current Assets 9.98b / Total Current Liabilities 5.71b)
Debt / Equity = 0.41 (Debt 7.23b / totalStockholderEquity, last quarter 17.8b)
Debt / EBITDA = 1.30 (Net Debt 4.92b / EBITDA 3.79b)
Debt / FCF = 7.88 (Net Debt 4.92b / FCF TTM 624.0m)
Total Stockholder Equity = 18.0b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.44% (Net Income -1.08b / Total Assets 30.4b)
RoE = -5.99% (Net Income TTM -1.08b / Total Stockholder Equity 18.0b)
RoCE = 2.34% (EBIT 542.0m / Capital Employed (Equity 18.0b + L.T.Debt 5.11b))
RoIC = 1.63% (NOPAT 423.4m / Invested Capital 25.9b)
WACC = 6.09% (E(22.1b)/V(29.4b) * Re(7.48%) + D(7.23b)/V(29.4b) * Rd(2.32%) * (1-Tc(0.22)))
Discount Rate = 7.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.55 | Cagr: -2.65%
[DCF] Terminal Value 73.10% ; FCFF base≈726.8m ; Y1≈637.4m ; Y5≈515.0m
[DCF] Fair Price = 13.57 (EV 8.27b - Net Debt 4.92b = Equity 3.35b / Shares 246.5m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -4
Revenue Correlation: 15.23 | Revenue CAGR: 1.05% | SUE: 1.16 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.89 | Chg30d=+0.00% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.98 | Chg30d=+5.91% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=3.56 | Chg30d=+1.91% | Revisions=+36% | GrowthEPS=-7.9% | GrowthRev=-25.7%
EPS next Year (2027-12-31): EPS=4.05 | Chg30d=+2.56% | Revisions=+36% | GrowthEPS=+13.8% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +37% (up=17, down=7)